Galapagos NV [GLPGA] vs Pharming Group N.V [PHARM] Detailed Stock Comparison
Galapagos NV
Euronext
Loading...
Pharming Group N.V
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Galapagos NV wins in 8 metrics, Pharming Group N.V wins in 10 metrics, with 0 ties. Pharming Group N.V appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Galapagos NV | Pharming Group N.V | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 51.71 | 57.15 | Galapagos NV |
| Price-to-Book Ratio | 0.71 | 3.01 | Galapagos NV |
| Debt-to-Equity Ratio | 0.32 | 53.57 | Galapagos NV |
| PEG Ratio | -40.71 | -105.20 | Pharming Group N.V |
| EV/EBITDA | 4.39 | 26.59 | Galapagos NV |
| Profit Margin (TTM) | -103.14% | -2.41% | Pharming Group N.V |
| Operating Margin (TTM) | -87.35% | 3.27% | Pharming Group N.V |
| EBITDA Margin (TTM) | N/A | 3.27% | N/A |
| Return on Equity | -10.39% | -3.70% | Pharming Group N.V |
| Return on Assets (TTM) | -5.11% | 2.85% | Pharming Group N.V |
| Free Cash Flow (TTM) | $-402.14M | $-2.59M | Pharming Group N.V |
| 1-Year Return | 21.85% | 41.67% | Pharming Group N.V |
| Price-to-Sales Ratio (TTM) | 6.81 | 2.12 | Pharming Group N.V |
| Enterprise Value | $-1.23B | $605.11M | Pharming Group N.V |
| EV/Revenue Ratio | -4.45 | 2.06 | Galapagos NV |
| Gross Profit Margin (TTM) | 92.79% | 90.38% | Galapagos NV |
| Revenue per Share (TTM) | $4 | $1 | Galapagos NV |
| Earnings per Share (Diluted) | $-4.38 | $-0.01 | Pharming Group N.V |
| Beta (Stock Volatility) | -0.05 | 0.54 | Galapagos NV |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Galapagos NV vs Pharming Group N.V Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Galapagos NV | -0.57% | -0.28% | 13.36% | 24.11% | 27.74% | 1.97% |
| Pharming Group N.V | -2.85% | 9.68% | 15.91% | 14.61% | 22.89% | 6.25% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Galapagos NV | 21.85% | -47.55% | -82.27% | -48.43% | 477.32% | 254.43% |
| Pharming Group N.V | 41.67% | 0.00% | -6.42% | 229.03% | -43.65% | -97.15% |
Performance & Financial Health Analysis: Galapagos NV vs Pharming Group N.V
| Metric | GLPGA | PHARM |
|---|---|---|
| Market Information | ||
| Market Cap | €1.88B | €720.78M |
| Market Cap Category | Large cap | Mid cap |
| 10 Day Avg. Volume | 175,991 | 15,657,064 |
| 90 Day Avg. Volume | 167,462 | 9,000,120 |
| Last Close | €28.00 | €1.02 |
| 52 Week Range | €20.00 - €31.08 | €0.65 - €1.10 |
| % from 52W High | -9.91% | -6.75% |
| All-Time High | €252.90 (Feb 17, 2020) | €459.55 (Jul 10, 2000) |
| % from All-Time High | -88.93% | -99.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.16% | 0.26% |
| Quarterly Earnings Growth | -0.16% | 0.26% |
| Financial Health | ||
| Profit Margin (TTM) | -1.03% | -0.02% |
| Operating Margin (TTM) | -0.87% | 0.03% |
| Return on Equity (TTM) | -0.10% | -0.04% |
| Debt to Equity (MRQ) | 0.32 | 53.57 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €40.12 | €0.35 |
| Cash per Share (MRQ) | €46.91 | €0.18 |
| Operating Cash Flow (TTM) | €-278,547,008 | €26.79M |
| Levered Free Cash Flow (TTM) | €-33,690,752 | €20.01M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Galapagos NV vs Pharming Group N.V
| Metric | GLPGA | PHARM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 51.71 | 57.15 |
| Forward P/E | -40.71 | -105.20 |
| PEG Ratio | -40.71 | -105.20 |
| Price to Sales (TTM) | 6.81 | 2.12 |
| Price to Book (MRQ) | 0.71 | 3.01 |
| Market Capitalization | ||
| Market Capitalization | €1.88B | €720.78M |
| Enterprise Value | €-1,227,399,424 | €605.11M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -4.45 | 2.06 |
| Enterprise to EBITDA | 4.39 | 26.59 |
| Risk & Other Metrics | ||
| Beta | -0.05 | 0.54 |
| Book Value per Share (MRQ) | €40.12 | €0.35 |
Financial Statements Comparison: Galapagos NV vs Pharming Group N.V
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GLPGA | PHARM |
|---|---|---|
| Revenue/Sales | €65.29M | €79.09M |
| Cost of Goods Sold | €4.71M | €8.32M |
| Gross Profit | €60.58M | €70.77M |
| Research & Development | €95.28M | €21.14M |
| Operating Income (EBIT) | €-57.03M | €-7.43M |
| EBITDA | €-44.29M | €-4.11M |
| Pre-Tax Income | €-104.42M | €-11.79M |
| Income Tax | €26,000 | €3.10M |
| Net Income (Profit) | €-105.75M | €-14.89M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GLPGA | PHARM |
|---|---|---|
| Cash & Equivalents | €108.07M | €60.09M |
| Total Current Assets | €3.47B | €214.11M |
| Total Current Liabilities | €437.04M | €77.54M |
| Long-Term Debt | €7.79M | €110.36M |
| Total Shareholders Equity | €2.75B | €215.29M |
| Retained Earnings | €-280.81M | €-292.80M |
| Property, Plant & Equipment | N/A | €24.23M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GLPGA | PHARM |
|---|---|---|
| Operating Cash Flow | €-42.99M | €2.07M |
| Capital Expenditures | €-5.10M | N/A |
| Free Cash Flow | €-43.86M | €-56,000 |
| Debt Repayment | €-1.01M | €-715,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLPGA | PHARM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 175,991 | 15,657,064 |
| Average Daily Volume (90 Day) | 167,462 | 9,000,120 |
| Shares Outstanding | 65.90M | 680.31M |
| Float Shares | 65.05M | 670.71M |
| % Held by Insiders | 0.25% | 0.01% |
| % Held by Institutions | 0.32% | 0.12% |
Dividend Analysis & Yield Comparison: Galapagos NV vs Pharming Group N.V
| Metric | GLPGA | PHARM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |